#Asthma may be one of the most common diseases, yet it’s still difficult to manage. The introduction of #biologics has been nothing short of revolutionary because physicians now have more options to treat #severeasthma. But even if a biologic is effective in controlled clinical trials, it doesn’t always mean it can help any and every patient in real life. This is where registries come in; by obtaining real-world evidence. Registries can provide information on the actual effectiveness of drugs in real-life. And such information can help tailor treatments for patients. #ISAR, the first global severe asthma registry, has been able to provide real-world findings that can inform clinical practice. For example, the FIRE study found anti–IL-5/5R therapy to be more effective than anti-IgE therapy in patients eligible for both.
Follow this link for even more interesting findings from registries! https://lnkd.in/gAJTJT5s
Also, check out this figure that shows the efficacy and effectiveness of drugs in different study designs!
